Ankui Yang
Papers
4
Total Citations
23
H-Index
3
About
Ankui Yang is a clinician-researcher specializing in head and neck oncology, with a particular focus on transoral robotic surgery (TORS) and innovative treatment strategies for oropharyngeal squamous cell carcinoma (OPSCC). Working at the intersection of surgical oncology and immuno-oncology, Yang has made significant contributions to advancing minimally invasive surgical approaches and neoadjuvant therapy protocols in the context of HPV-associated oropharyngeal cancer — a rapidly evolving field with major implications for treatment de-escalation. Among Yang's most notable achievements is the design and execution of a pioneering single-arm, two-centre Phase II clinical trial evaluating neoadjuvant sintilimab (an anti-PD-1 immunotherapy) combined with platinum-doublet chemotherapy prior to transoral surgery for HPV-positive oropharyngeal cancer. This work, accumulating nearly 10 citations across related publications since 2024, represents a forward-thinking effort to improve pathological response rates while potentially reducing long-term treatment toxicity. Yang's earlier analyses of T1–T2 OPSCC patients treated with TORS in China — the most cited work with 12 citations — helped establish the clinical safety and efficacy of robotic surgery in both HPV-positive and HPV-negative populations, filling an important gap in Asian clinical data and cementing Yang's reputation as a leader in surgical innovation for oropharyngeal malignancies.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4